ITARECIPE: Italian Registry Chronic Pancreatitis

Sponsor
Associazione Italiana per lo Studio del Pancreas (Other)
Overall Status
Recruiting
CT.gov ID
NCT05733130
Collaborator
(none)
1,500
1
62.7
23.9

Study Details

Study Description

Brief Summary

ITARECIPE is a multicenter national registry designed to study the diagnosis and evolution of Chronic Pancreatitis

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Chronic pancreatitis (PC) is a relatively rare disease (45/100,000 population) in Italy, with heterogeneous aetiology, clinical history and treatment.

    Patients need to be treated by different specialists, but almost always the gastroenterologist is central in diagnosis and treatment.

    The study will be the first National Registry, prospective and will collect data on the history of the disease and its outcomes.

    Data will be collected through an electronic data collection form (e-CRF) that the Sponsor (AISP) will make available to the Participating Centres.

    Patients enrolled will be both new diagnoses or follow-up visits of patients with a diagnosis already made no more than 1 year before the signing of informed consent for the study in question: only data on the diagnosis and follow-up visits prior to the signing of the informed consent will be collected retrospectively (no more than one year).

    Data from patients visited in the Centres included in the study will be collected prospectively.

    In addition to the first visits, data will also be collected on follow-up visits that are scheduled according to the clinical need of each patient, which differ according to the stage of the disease

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    1500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Registro Italiano Pancreatite Cronica
    Actual Study Start Date :
    Oct 10, 2022
    Anticipated Primary Completion Date :
    Dec 31, 2027
    Anticipated Study Completion Date :
    Dec 31, 2027

    Outcome Measures

    Primary Outcome Measures

    1. Disease Progression [5 years]

      The collection of data on disease progression in terms of the need for medical, endoscopic or surgical therapy, the risk of pancreatic exo-endocrine failure and the risk of developing pancreatic and extrapancreatic complications and death.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age >/= 12 years;

    • Diagnosis "definite" or "probable" according to the "M-ANNHEIM" criteria;

    • First evidence of diagnosis within 12 months of enrolment.

    Exclusion Criteria:
    • Age < 12 years;

    • History of known disease with certainty for > 12 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IRCCS Ospedale San Raffaele Milan Italy 20132

    Sponsors and Collaborators

    • Associazione Italiana per lo Studio del Pancreas

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Associazione Italiana per lo Studio del Pancreas
    ClinicalTrials.gov Identifier:
    NCT05733130
    Other Study ID Numbers:
    • ITARECIPE
    First Posted:
    Feb 17, 2023
    Last Update Posted:
    Feb 17, 2023
    Last Verified:
    Feb 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Associazione Italiana per lo Studio del Pancreas
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 17, 2023